Growth Factor News and Research

RSS

Columbia Engineering professor wins grant to study tendon-to-bone integration for rotator cuff repair

Helen H. Lu, professor of biomedical engineering at Columbia Engineering, has won a three-year $1.125 million Translational Research Award grant from the Department of Defense's Congressionally Directed Medical Research Programs for her research on tendon-to-bone integration for rotator cuff repair.

16 Dec 2015

Report uncovers how Down syndrome hampers nervous system that plays key role in health, longevity

While most Down syndrome research has focused on the brain, a new report by Johns Hopkins University biologists uncovers how the disorder hampers a separate part of the nervous system that plays a key role in health and longevity.

14 Dec 2015

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis.

12 Dec 2015

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Pulmonary hypertension is an umbrella term used for many conditions that all result in elevation of the pulmonary arterial pressure. Of interest, many of these completely different clinical and pathophysiological entities result in a final common pathway of vasoconstriction, micro thrombosis and vascular remodelling.

10 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.

7 Dec 2015

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

Study reveals why colorectal cancer still returns in some patients after treatment

Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.

17 Nov 2015

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.

17 Nov 2015

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).

15 Nov 2015

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

15 Nov 2015

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

14 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

New treatment may help patients with chronic renovascular disease

A new treatment may help patients with a chronic kidney condition that can also lead to heart problems and premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

6 Nov 2015

Growth Factor News and Research

Columbia Engineering professor wins grant to study tendon-to-bone integration for rotator cuff repair

Report uncovers how Down syndrome hampers nervous system that plays key role in health, longevity

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Study reveals why colorectal cancer still returns in some patients after treatment

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

New findings reveal association between colorectal cancer and melanoma drug treatment

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

AACR rapid and dramatic responses in TRK fusion patients

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

New tool could help identify patients most likely to benefit from chemoprevention

New treatment may help patients with chronic renovascular disease

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News